Policy / European Union
EMA Approves Strimvelis: A Groundbreaking Gene Therapy for ADA-SCID
Strimvelis, an innovative gene therapy for treating severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID), has been approved for use in the EU, offering hope to patients without suitable bone marrow donors.
Updated
Affected: European readers
European Union
08 May 2026